title: Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites.
abstract: OBJECTIVE
  The MELDNa score was developed to improve the prognostic value of the MELD score in cirrhosis and was built for serum sodium concentrations numerically capped between 125 and 140 mmol/L. This model is not validated in a well-defined population of patients with cirrhosis and refractory ascites in whom severe hyponatremia (≤ 125 mmol/L) is frequent. This study assessed the prognostic value of severe hyponatremia and the MELDNa score in these patients.
  
  
  METHODS
  A consecutive, single-centre, observational, prospective study was performed in patients with cirrhosis and refractory ascites defined according to the International Ascites Club criteria. The prevalence of low serum sodium was assessed in this population. Predictive factors of mortality were analyzed and compared.
  
  
  RESULTS
  One hundred seventy-four patients were included. Sixty-six (37.9%) had low serum sodium (< 130 mmol/L). Sixty-one (35.1%) had diuretic-intractable ascites due to severe hyponatremia (≤ 125 mmol/L). The median MELDNa score was 23 (10-33). The 1-year cumulative incidence of death was 55% (95% CI: 55-56%). The best predictive factors of mortality were the following: severe hyponatremia (≤ 125 mmol/L) as an underlying cause of refractory ascites, a higher Child-Pugh score, beta-blocker therapy, and a high frequency of large-volume paracentesis. The Child-Pugh score had a higher area under receiver operating curve to predict mortality than MELDNa.
  
  
  CONCLUSIONS
  In patients with cirrhosis and refractory ascites, severe hyponatremia and Child-Pugh score are better predictors of mortality than MELDNa.
authors.affiliation: Service d'Hépatologie, Hôpital Beaujon, Clichy, France. thomas.serste@skynet.be
authors.forename: Thomas
authors.initials: T
authors.lastname: Sersté
authors.forename: Thierry
authors.initials: T
authors.lastname: Gustot
authors.forename: Pierre-Emmanuel
authors.initials: PE
authors.lastname: Rautou
authors.forename: Claire
authors.initials: C
authors.lastname: Francoz
authors.forename: Hassane
authors.initials: H
authors.lastname: Njimi
authors.forename: Francois
authors.initials: F
authors.lastname: Durand
authors.forename: Dominique
authors.initials: D
authors.lastname: Valla
authors.forename: Didier
authors.initials: D
authors.lastname: Lebrec
authors.forename: Richard
authors.initials: R
authors.lastname: Moreau
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001201:Ascites / Q000401:mortality*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007010:Hyponatremia / Q000401:mortality*; D008103:Liver Cirrhosis / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D012964:Sodium / Q000097:blood
chemical_list: D000319:Adrenergic beta-Antagonists; D012964:Sodium